文献速递重症综合管理与镇静镇痛儿科与产科急症复苏、休克与脓毒症

液体过负荷的程度与时机对危重患儿结局的影响:来自多中心国际AWARE研究的报告

Impact of the Magnitude and Timing of Fluid Overload on Outcomes in Critically Ill Children: A Report From the Multicenter International Assessment of Worldwide Acute Kidney Injury, Renal Angina, and Epidemiology (AWARE) Study.
PubMed 文献 · Crit Care Med · 2023-02-17
一句话结论多中心前瞻性队列显示,危重患儿ICU第1天结束即出现液体过负荷≥5%即与不良结局相关,第1天≥10%及第2天≥5%/≥10%与死亡率升高和ICU/无呼吸机天数减少相关。

该研究为前瞻性队列,纳入32个儿科ICU连续收治的5079例危重患儿,评估液体过负荷(FO)在预设阈值和时间点(ICU第1天末和第2天末FO≥5%、FO≥10%)的流行病学及与结局的关联。FO各阈值常见:第1天FO≥5%占38.1%(n=1753)、FO≥10%占11.7%(n=537),第2天FO≥5%占53.3%(n=1539)、FO≥10%占25.1%(n=724)。多因素模型显示,第1天FO≥5%与无ICU天数减少相关,第1天FO≥10%与死亡率升高及无ICU天数、无呼吸机天数减少相关;FO峰值、第2天FO≥5%和第2天FO≥10%均与死亡率升高及无ICU天数、无呼吸机天数减少相关。作者认为,这些新发现有助于指导针对临床相关液体过负荷的治疗和预防干预策略及试验的制定。

要点

  • 危重患儿ICU第1天末FO≥5%即与无ICU天数减少相关,FO≥10%与死亡率升高及无ICU、无呼吸机天数减少相关。
  • 第2天末FO≥5%(53.3%,n=1539)和FO≥10%(25.1%,n=724)均与死亡率升高及无ICU、无呼吸机天数减少相关。
  • FO峰值与死亡率升高及无ICU、无呼吸机天数减少相关。
  • 第1天末FO≥5%见于38.1%(n=1753)的患儿,FO≥10%见于11.7%(n=537),提示轻中度液体过负荷在危重患儿中常见。
  • 作者认为,FO≥5%第1天、FO≥10%第1天、FO≥5%第2天和FO≥10%第2天这些时机与数量的关键组合有助于指导干预策略和试验的制定。

适用人群与场景

  • 32个儿科ICU连续收治的5079例危重儿童和年轻成人,作为全球急性肾损伤、肾绞痛和流行病学评估研究(AWARE)的一部分。

诊断标准与关键阈值

  • 液体过负荷阈值与时间点:ICU第1天末FO≥5%和FO≥10%,ICU第2天末FO≥5%和FO≥10%。

研究设计与关键结果

  • 研究设计:前瞻性队列研究,国际多中心协作,32个儿科ICU,纳入5079例连续收治的危重儿童和年轻成人,无干预。
  • FO阈值出现频率:第1天FO≥5%为38.1%(n=1753),第1天FO≥10%为11.7%(n=537),第2天FO≥5%为53.3%(n=1539),第2天FO≥10%为25.1%(n=724)。
  • 第1天多因素模型:FO≥5%与无ICU天数减少相关;FO≥10%与死亡率升高及无ICU天数、无呼吸机天数减少相关。
  • 多因素模型:FO峰值、第2天FO≥5%、第2天FO≥10%均与死亡率升高及无ICU天数、无呼吸机天数减少相关。

证据类型、等级与局限

  • 证据类型:前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,FO≥5%第1天、FO≥10%第1天、FO≥5%第2天和FO≥10%第2天这些时机与数量的关键组合与不良结局相关,将有助于指导针对临床相关液体过负荷的治疗和预防干预策略及试验的制定。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: With the recognition that fluid overload (FO) has a detrimental impact on critically ill children, the critical care nephrology community has focused on identifying clinically meaningful targets for intervention. The current study aims to evaluate the epidemiology and outcomes associated with FO in an international multicenter cohort of critically ill children. The current study also aims to evaluate the association of FO at predetermined clinically relevant thresholds and time points (FO ≥ 5% and FO ≥ 10% at the end of ICU days 1 and 2) with outcomes.

DESIGN: Prospective cohort study.

SETTING: Multicenter, international collaborative of 32 pediatric ICUs.

PATIENTS: A total of 5,079 children and young adults admitted consecutively to pediatric ICUs as part of the Assessment of the Worldwide Acute Kidney Injury, Renal Angina and Epidemiology Study.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: The FO thresholds at the time points of interest occurred commonly in the cohort (FO ≥ 5%Day1 in 38.1% [ n = 1753], FO ≥ 10%Day1 in 11.7% [ n = 537], FO ≥ 5%Day2 in 53.3% [ n = 1,539], FO ≥ 10%Day2 in 25.1% [ n = 724]). On Day1, multivariable modeling demonstrated that FO ≥ 5% was associated with fewer ICU-free days, and FO ≥ 10% was associated with higher mortality and fewer ICU and ventilator-free days. On multivariable modeling, FO-peak, Day2 FO ≥ 5%, and Day2 FO ≥ 10% were associated with higher mortality and fewer ICU and ventilator-free days.

CONCLUSIONS: This study found that mild-to-moderate FO as early as at the end of ICU Day1 is associated with adverse outcomes. The current study fills an important void in the literature by identifying critical combinations of FO timing and quantity associated with adverse outcomes (FO ≥ 5%Day1, FO ≥10%Day1, FO ≥ 5%Day2, and FO ≥ 10%Day2). Those novel findings will help guide the development of interventional strategies and trials targeting the treatment and prevention of clinically relevant FO.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Selewski DT, Gist KM, Basu RK, et al. Impact of the Magnitude and Timing of Fluid Overload on Outcomes in Critically Ill Children: A Report From the Multicenter International Assessment of Worldwide Acute Kidney Injury, Renal Angina, and Epidemiology (AWARE) Study. Crit Care Med. 2023. PMID: 36821787. doi:10.1097/CCM.0000000000005791

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。